Royal Bank Of Canada An2 Therapeutics, Inc. Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$5.06 - $9.91 $2,307 - $4,518	-456 Reduced 71.03%	186 $1,000
Q1 2023 May 15, 2023	SELL	$7.94 - $15.6 $8,805 - $17,300	-1,109 Reduced 63.34%	642 $6,000
Q4 2022 Feb 14, 2023	BUY	$8.51 - $16.78 $14,398 - $28,391	1,692 Added 2867.8%	1,751 $16,000
Q3 2022 Nov 14, 2022	BUY	$7.61 - $22.29 $243 - $713	32 Added 118.52%	59 $1,000
Q2 2022 Aug 15, 2022	BUY	$7.7 - $18.82 $207 - $508	27 New	27 $0

13.2M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $40.7M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.